Articles tagged with Antibodies
A study at Technical University of Munich found that antibodies can activate human nerve cells within milliseconds, modifying their function. This knowledge improves understanding of illnesses associated with certain types of cancer and paraneoplastic syndromes, which occur when the body's autoimmune reaction attacks its own cells.
A new study found that abnormal antibody production in the intestine of people with HIV-1 may lead to chronic inflammation and AIDS despite treatment. The research revealed that immune system cells in the intestines have decreased capacity to produce mature antibodies.
A study led by NYU Langone researchers identified CD99, a protein-sugar molecule, as a potential therapeutic target for blood stem cell cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Antibodies against CD99 can selectively kill cancer stem cells while sparing normal blood stem cells.
Researchers at UNC have engineered platelets to carry cancer-fighting antibodies, allowing them to target and kill microtumors before they can grow or spread. This innovative approach has shown promising results in animal studies, potentially offering a new hope for patients with recurring cancer after surgery.
A UCF researcher has developed a method that uses nanoparticles and Faraday rotation to measure protein quantities in test solutions, allowing for faster biochemical immunology test results. This technique could lead to faster diagnoses for HIV, Lyme disease, syphilis, and other infectious conditions.
Researchers at UM SOM and SOD published 22 articles on infectious agents, vaccines, and immune system activation. Studies focused on Ebola, Clostridium difficile, biofilms, and other topics, advancing knowledge in infection and immunity research.
Researchers at Uppsala University developed a new antibody design that increases brain uptake of antibodies almost 100-fold, offering new opportunities for treating brain diseases. The modified antibodies use the transferrin receptor to transport them across the blood-brain barrier.
WPI researchers develop a liquid biopsy chip that can trap and identify metastatic cancer cells in small amounts of blood. The device uses antibodies attached to carbon nanotubes, which create an electrical signature that can be detected to identify captured cells.
A study found that patients with oropharyngeal cancer who recur have higher levels of antibodies for proteins E6 and E7, which can detect recurrence before it's diagnosed. This biomarker could provide an early window for treatment.
Researchers at the University of Birmingham found that antibody levels in saliva are linked to those in blood serum, suggesting a non-invasive method for assessing immunity. Higher antibody concentrations in serum were associated with higher concentrations in saliva, particularly for IgA antibodies.
Researchers developed a vaccine that stimulates an antibody targeting pathological tau, discovering its Achilles' heel. The antibody avoids immune reaction towards the body by coupling to a carrier molecule.
Research shows that blocking type I interferon signaling can enhance the effectiveness of antiretroviral therapy (cART) in HIV-infected mice. By targeting IFN-I signaling, antibodies were able to reduce chronic immune activation and viral load, leading to improved infection management.
A new study suggests that blood-borne HPV antibodies can serve as a reliable biomarker for predicting the outcome of all types of head and neck cancer. The researchers found that patients with an immune response to HPV have a lower risk of dying during the five-year follow-up period, regardless of the exact location of their tumors.
ADC MI130110 shows remarkable antitumoral activity in CD13-expressing tumor cells, impairing tubulin polymerization and disrupting the microtubule network. The treatment resulted in significant reduction in tumor size, complete remission, and increased median survival time.
Scientists have created peptide probes that attach to proteins with comparable efficiency to antibodies, improving image resolution. These probes can help shed light on protein layout and quantification, opening new possibilities for neurobiological research.
Researchers at Duke University have developed a new PEG delivery system that avoids immune responses and extends the duration of drugs in the bloodstream. The technology, which produces more uniform results, shows excellent efficacy in controlling glucose levels in diabetic mice.
Researchers at Duke-NUS Medical School have discovered how the human antibody C10 prevents Zika infection by locking proteins into place, preventing viral DNA entry. Disrupting fusion with C10 may be more effective than targeting docking in preventing Zika infection.
Researchers found that 2-dose HPV vaccine regimens for girls and boys aged 9-14 years had noninferior antibody responses compared to 3-dose regimens for adolescent girls and young women. The study suggests using a 2-dose schedule could improve adherence to HPV vaccination programs and reduce healthcare costs.
Researchers at Georgia Institute of Technology enhance atomic force microscopy by adding electronic white noise to detect molecular interactions in slow motion. This improvement allows for the measurement of varying shades of gray, enabling a more detailed understanding of molecule binding and unbinding.
Researchers at UT Austin report that conventional flu vaccines may not be effective, and a new class of antibodies could protect against multiple strains. The study discovered a new approach to identifying and quantifying antibodies in human blood, allowing for more precise understanding of vaccine efficacy.
Antibody drug conjugates (ADCs) have shown efficacy and acceptable toxicity, surpassing radionuclide conjugates in certain tumor types. Targeting cancer stem cells may further improve treatment outcomes.
A 75-million-year-old Mongolian oviraptor fossil preserved the original keratinous claw sheath that covered its digits. The study adds to evidence that organic materials can preserve over time, revealing details about how proteins might be preserved.
Researchers have identified a human antibody that prevents Zika virus infection in pregnant mice and protects adult mice. The antibody also prevented damage to the placenta and fetuses, suggesting it may be used to prevent Zika-related birth defects.
A mouse study found an antibody can soothe raging, nerve-driven poison ivy itch by blocking an immune system protein. The researchers also discovered that blocking another receptor for the protein alleviates itch, paving the way for potential treatments.
Scientists developed two types of llama antibody that can specifically mark and show amyloid plaques and neurofibrillary tangles, the characteristic lesions of Alzheimer's disease. These antibodies have the rare ability to cross the blood-brain barrier, allowing for non-invasive detection.
Researchers found that the key viral protein used in candidate HCV vaccines is surprisingly flexible, elicit a wide variety of antibodies that cannot block viral infection. This flexibility may be why current vaccines have been ineffective in preventing HCV infection.
Scientists at the University of Basel discovered that chronic viral infections lead to an inadequate immune response due to prolonged inflammation. This hasty reaction by B cells produces antibodies quickly but also leads to their rapid depletion, resulting in a short-lived and unsustainable defense against the virus.
Three different candidate Zika vaccines have been found to protect rhesus monkeys against the disease in trials. The vaccines, tested in preclinical trials, were found to be effective at warding off infection by the Zika virus strain circulating in Brazil and Puerto Rico.
Researchers at Michigan Technological University provide a detailed overview of Zika's history, transmission modes, and risks, including sexual transmission and miscarriage risks. The study also highlights the connection between dengue virus infection and Zika virus exacerbation.
A new device uses a forest-like array of vertically-aligned carbon nanotubes to selectively trap viruses by size, increasing sensitivity by over 100 times. This technology can capture unknown viruses without antibodies or sequence information, enabling early detection and potential vaccine development.
Research on therapeutic antibodies for spinal cord injury reveals potential applications in myelin repair, neuroprotection, axon outgrowth, and anti-immune reaction. Several antibodies are reviewed as reagents to promote neurite outgrowth and inhibit immune responses.
Scientists have developed a two-pronged antibody that can counteract the unique immune-evasion mechanism of filoviruses like Ebola. The antibody, called a 'Trojan horse' antibody, targets the glycoprotein on the outside of the virus and prevents it from associating with a specific host-cell receptor in the endosome.
Developed by an antibody that blocks clot formation without triggering bleeding, the new blood thinner could be used to treat patients with heart and vascular diseases. Researchers also created a second antibody to rapidly reverse its effects, addressing safety concerns.
Activated B cells play a crucial role in the formation of immune memory, with some cells persisting for months after initial exposure. The study reveals that while plasmablasts dominate early responses to infections or vaccinations, activated B cells take center stage later on.
Researchers found that naturally infected chimpanzees developed antibodies able to neutralize multiple AAV serotypes, a hurdle for gene therapy. The study provides insights into the immune response to natural AAV infection and its implications for gene delivery strategies.
Two vaccine candidates have shown complete protection against the Zika virus in rhesus monkeys, with no adverse effects observed. The findings, published in the journal Science, provide a promising lead for developing a safe and effective human vaccine to combat this mosquito-borne disease.
Researchers found that adding anti-PCSK9 antibodies to existing treatments can significantly reduce LDL cholesterol levels in patients. The studies demonstrated a reduction in LDL cholesterol and achieved high response rates for both alirocumab and evolocumab.
Researchers at WashU Medicine have identified six antibodies capable of protecting against Zika virus infection in mice, providing crucial information on how these antibodies interact with the virus. The discovery could lead to the development of a vaccine, diagnostic tests, and potentially new therapies for Zika-related diseases.
A team of researchers has identified the mechanisms behind excessive antibody production in chronic infections, discovering a link between B-cell activation and type 1 interferons. Proteins like endosomal TLRs trigger proinflammatory responses, leading to increased B-cell antibody production and potentially exacerbating conditions.
Researchers tested serum antibodies from Ebola survivors and found substantial cross-reactivity with other filoviruses, suggesting long-lived immunity. The study's results indicate that antibody responses extend beyond the primary virus, imparting at least partial immunity to other filoviral infections.
Researchers at Osaka University identified a human immune receptor that detects pathogenic microorganism invasion, which recognizes cleaved antibodies and fights immune evasion mechanisms. This discovery contributes to the development of new treatments and prevention strategies against infectious diseases.
La Jolla Institute researchers reveal a powerful arm of the immune system that drives maturation of helper T cells. Their study identifies activin A as a key factor, which could lead to more potent vaccines and treatments for autoimmune diseases.
Researchers have discovered two antibodies that can efficiently neutralize both dengue and Zika viruses, sharing identical binding sites on their viral envelopes. This breakthrough could lead to the development of a single vaccine offering protection against both diseases.
A study from Imperial College London found that previous exposure to the dengue virus may increase the potency of Zika infection, potentially leading to more severe symptoms. The research suggests that the Zika virus uses the body's own defences as a 'Trojan horse', allowing it to enter human cells undetected and replicate rapidly.
Scientists at Helmholtz Zentrum München have developed a novel antibody targeting carbonic anhydrase XII, which is overexpressed in cancer cells, with the goal of improving treatment options for glioblastoma patients. The antibody conjugated with lutetium-177 can deliver lethal doses to tumor cells directly.
Researchers have developed a method using tiny alpaca-derived nanobodies to identify and target specific proteins involved in viral infections. By using these molecules to perturb cellular processes, scientists can tease apart the roles individual proteins play in disease, leading to potential new treatments for infectious diseases.
Researchers found that mosquito saliva increases endothelial permeability, enhances immune cell migration, and promotes the spread of dengue virus during antibody-dependent enhancement. This study suggests a critical role of mosquito saliva in exacerbating dengue disease severity.
Researchers developed Camelid antibodies against serine proteases to study catalysis and inhibition. These findings have significant implications for disease treatment and diagnosis involving these enzymes.
A new study published in the New England Journal of Medicine found that patients with severe hemophilia A who received human plasma-based treatments developed inhibitors at a lower rate than those who received recombinant Factor VIII. This could lead to more effective treatment options for families affected by this rare genetic condition.
Researchers found that DNASE1L3 prevents lupus by breaking down DNA, which triggers immune cells to produce antibodies that cause inflammation. A new mechanism for biologic therapies has been discovered.
Early findings suggest carfilzomib may provide improved reduction of antibodies in potential kidney transplant candidates with reduced side effects. The study's preliminary data show antibody reductions between 31 to 100 percent in the first group of six patients.
A study presented at EULAR 2016 found that patients with antibodies to biological infliximab are less likely to benefit from infliximab biosimilar (CT-P13). The presence of these anti-infliximab antibodies can lead to a loss of response and increased risk of side effects. The findings suggest that antibody-positive patients should not ...
Researchers have developed a non-toxic transplantation procedure using antibodies to target blood stem cells, making it potentially safer and more effective than current methods. The new treatment removes nearly all blood stem cells, offering hope for patients with blood disorders like sickle cell anemia.
Researchers found that anti-DNA antibodies preferentially bind to damaged double-stranded DNA (dsDNA) over native DNA, contributing to the pathogenesis of autoimmune diseases. This study provides mechanistic insight into the formation and properties of pathogenic anti-DNA antibodies.
Scientists at Aarhus University used X-rays to study eculizumab's mechanism. They found the antibody creates a physical barrier preventing C5 cleaving enzymes from forming contacts.
Researchers have discovered a new protein compound that binds to two HER2 receptors simultaneously, preventing growth signals and killing cancer cells. This innovative solution shows great promise in treating invasive breast cancer more effectively.
A new study reveals that breast milk immunoglobulin G (IgG) antibodies play a critical role in helping newborn mice tolerate beneficial gut microbes. This finding challenges previous research suggesting IgA antibodies are primarily responsible for teaching the neonatal immune system to tolerate gut microbes.
Researchers at UC Berkeley discover that antibodies in mother's milk help promote a healthy balance between gut microbes and the mammalian host, preventing chronic inflammatory conditions. The study sheds light on how these antibodies interact with the newborn's immune system to establish lifelong immune responses.
A phase I trial of the rVSV-ZEBOV vaccine in Africa and Europe has shown promising results, with antibodies detectable after six months. The vaccine stimulates a strong immune response and appears to control virus replication.
A new study analyzing 5,000 stored blood samples found no increase in food-specific IgE antibodies between the 1980s and 2000s. The researchers suggest that growing awareness and diagnosis of food allergies among children may be contributing to the increasing prevalence of food allergies over the past few decades.